Skip to content
Screener

Total Equity at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
$8.61B+1.6%
Veracyte logo
VeracyteVCYT
$1.34B+12.5%
Lucid Diagnostics logo
Lucid DiagnosticsLUCD
$4M+174%
Myriad Genetics logo
Myriad GeneticsMYGN
$337.4M-52.1%
Personalis, Inc. logo
Personalis, Inc.PSNL
$254.77M+22.9%
NeoGenomics logo
NeoGenomicsNEO
$785.73M-8.0%

Other financials

Income statement

See full
Revenue$83.7M-4.9%
Gross profit$63.1M-11.8%
Operating income-$18.4M+34.1%
Net income-$14.5M+43.8%
EPS (diluted)-$0.49+45.6%

Balance sheet

See full
Cash & equivalents$63.8M-28.9%
Total debt$36.7M+42.1%
Total assets$547.8M+9.2%

Cash flow

See full
Operating cash flow-$22.1M-267%
CapEx$12.5M+163%
Free cash flow-$34.6M-221%

Valuation

See full
Market cap$978.5M+76.1%
Enterprise value$951.46M+86.2%
P/S2.9×+1.3×

Profitability

See full
Gross margin77.9%-4.1pp
Operating margin-9.8%-30.8pp
Net margin-3.8%-10.2pp
FCF margin1.3%-10.7pp

Returns & leverage

See full
Return on equity-2.8%-10.6pp
Debt / equity0.1×0.0×
Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:09 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-031263
ASSETSMarch 31, 2026 / (unaudited)December 31, 2025
Stockholders’ Equity
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued and outstanding as of March 31, 2026 and December 31, 2025
Common stock, $0.001 par value per share; 200,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 30,295,965 and 29,686,314 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively3030
Additional paid-in capital700,255694,860
Accumulated deficit(238,806)(224,284)
Accumulated other comprehensive (loss) income(63)267
Total stockholders’ equity461,416470,873
Total liabilities and stockholders’ equity$547,805$578,556

Item 1. Financial Statements.

FAQ

What is Castle Biosciences's total equity?
Castle Biosciences (CSTL) reported total equity of $461.42M in Q1 2026.
How has Castle Biosciences's total equity changed year-over-year?
Castle Biosciences's total equity increased by 4.8% year-over-year, from $440.31M to $461.42M.
What is the long-term trend for Castle Biosciences's total equity?
Over 5 years (2020 to 2025), Castle Biosciences's total equity has grown at a 2.5% compound annual growth rate (CAGR), from $415.69M to $470.87M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Castle Biosciences's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude